Products for Research Use Only
RegisterLogin

Otamixaban

CAT: 0804-HY-70035-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-70035-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Otamixaban (FXV673) is a potent (Ki = 0.5 nM), selective, rapid acting, competitive and reversible fXa inhibitor that effectively inhibits both free and prothrombinase-bound fXa. IC50 value: Target: Factor Xa Otamixaban is a potent (Ki = 0.5 nM), selective, rapid acting, competitive and reversible fXa inhibitor that effectively inhibits both free and prothrombinase-bound fXa. In vivo experiments have demonstrated that Otamixaban is highly efficacious in rodent, canine and porcine models of thrombosis. In addition, recent clinical findings indicate that Otamixaban is efficacious, safe and well tolerated in humans and therefore has considerable potential for the treatment of acute coronary syndrome. This review article chronicles the discovery and pre-clinical data surrounding the fXa inhibitor Otamixaban as well as the recent clinical findings in humans.
CAS Number
193153-04-7
Product Name Alternative
FXV673
UNSPSC
12352005
Target
Factor Xa
Type
Reference compound
Related Pathways
Metabolic Enzyme/Protease
Applications
COVID-19-immunoregulation
Field of Research
Cardiovascular Disease
Assay Protocol
https://www.medchemexpress.com/Otamixaban.html
Purity
98.25
Solubility
DMSO : 50 mg/mL (ultrasonic)
Smiles
N=C(C1=CC=CC(C[C@@H](C(OC)=O)[C@H](NC(C2=CC=C(C=C2)C3=CC=[N+]([O-])C=C3)=O)C)=C1)N
Molecular Formula
C25H26N4O4
Molecular Weight
446.50
References & Citations
[1]Eikelboom JW, Weitz JI.Otamixaban in acute coronary syndromes.Lancet. 2009 Sep 5;374 (9692) :762-4. Epub 2009 Aug 28.|[2]Sabatine MS, Antman EM, et al. Otamixaban for the treatment of patients with non-ST-elevation acute coronary syndromes (SEPIA-ACS1 TIMI 42) : a randomised, double-blind, active-controlled, phase 2 trial.Lancet. 2009 Sep 5;374 (9692) :787-95. Epub 2009 Aug 28.|[3]Guertin KR, Choi YM.The discovery of the Factor Xa inhibitor otamixaban: from lead identification to clinical development.Curr Med Chem. 2007;14 (23) :2471-81.|[4]Cohen M, Bhatt DL, et al. SEPIA-PCI Trial Investigators.Randomized, double-blind, dose-ranging study of otamixaban, a novel, parenteral, short-acting direct factor Xa inhibitor, in percutaneous coronary intervention: the SEPIA-PCI trial.Circulation. 2007 May 22;115 (20) :2642-51. Epub 2007 May 14.|[5]Guertin, Kevin R.; Choi, Yong-Mi.The discovery of the factor Xa inhibitor Otamixaban: from lead identification to clinical development.Current Medicinal Chemistry (2007), 14 (23), 2471-2481.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 3

Alternative Products

CatalogName
A3690-100Otamixaban
T71835-01Otamixaban HCl
MBS386827-01Otamixaban (FXV 673)
A11517-100Otamixaban (FXV 673) 100mg
A11517-50Otamixaban (FXV 673) 50mg
A11517-25Otamixaban (FXV 673) 25mg
A11517-10Otamixaban (FXV 673) 10mg
A11517-5Otamixaban (FXV 673) 5mg
A11517-2Otamixaban (FXV 673) 2mg

Popular Products